Beam Therapeutics shares are trading lower after Verve Therapeutics paused enrollment in its Heart-1 clinical trial. Verve and Beam previously entered a license agreement for access to Beam's base editing, gene editing, and delivery technologies.
Benzinga Newsdesk - Apr 2, 2024, 3:30PM